Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Vida Health Hires Ravi Guha as Chief Financial Officer


Virtual cardiometabolic care leader Vida Health announced the addition of Ravi Guha to its executive leadership team as Chief Financial Officer.

"I couldn't be more thrilled to have Ravi as part of our leadership team at Vida," said Vida Health CEO Joe Murad. "He has a wealth of value-based care and investment experience that I can't wait to tap into during this exciting time of growth for Vida."

Mr. Guha joins Vida from Heal, a home-based primary care and telehealth company recently acquired by Humana/Centerwell. While Heal's Chief Financial Officer, Mr. Guha spearheaded the company's transition from a fee-for-service urgent care provider to a value-based primary care model. Prior to Heal, Mr. Guha spent 17 years at Canyon Capital Advisors, a multi-asset multi-strategy investment firm, where he led the fund's investments in the healthcare space.

"It's an honor to be brought on to Vida to lead financial operations at this inflection point of growth for the company," said Mr. Guha. "The company's focus on obesity and diabetes management while guaranteeing outcomes becomes all the more important as companies grapple with rising pharmaceutical costs due to the rise of GLP-1's."

Vida's virtual cardiometabolic solutions serve members in all 50 states in both English and Spanish. Clients include employers like Boeing, Visa, General Motors, Cisco, and Bass Pro Shops, along with some of the country's largest health plans like Blue Cross Blue Shield plans, and Select Health. Vida has proven clinical outcomes across a range of conditions, including obesity, diabetes, congestive heart failure, chronic obstructive pulmonary disease, hypertension, depression, and anxiety. Vida is the only virtual chronic care solution in its class to guarantee outcomes through a value-based pricing structure that puts 100% of Vida's fees at risk for both physical and mental health outcomes.

About Vida Health

Vida Health is a virtual cardiometabolic clinic focused on treating diabetes and obesity with a body-and-mind approach. Vida's clinically validated programs combine an AI-powered, personalized mobile app experience with a national network of high-quality providers who work in a high-touch care team model that maximizes engagement, outcomes, and savings. Vida's app offers video sessions, asynchronous messaging, and digital content and programs to help people prevent and manage chronic conditions ? like diabetes, obesity, and hypertension ? and the mental conditions that accompany them ? like stress, depression, and anxiety. Some of America's largest employers and health plans trust Vida to deliver meaningful cardiometabolic outcomes for whole populations. Learn more at www.Vida.com.


These press releases may also interest you

at 06:25
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...



News published on and distributed by: